Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseaseTracy Cole(Ionis Pharmaceuticals (United States)), Katrina L. Paumier(Michigan State University)bioRxiv (Cold Spring Harbor Laboratory)November 4, 201910.1101/830554Cited by 10SaveCiteExport RISWatch citationsRelated Papersα-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease|JCI Insight|2021|136